Cargando…

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain. Lomustine is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomustine. A multicentre phase I/II study was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larkin, J M G, Hughes, S A, Beirne, D A, Patel, P M, Gibbens, I M, Bate, S C, Thomas, K, Eisen, T G, Gore, M E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360201/ https://www.ncbi.nlm.nih.gov/pubmed/17146474 http://dx.doi.org/10.1038/sj.bjc.6603503

Ejemplares similares

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
por: Patil, Vijay M., et al.
Publicado: (2022)

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
por: Weller, J., et al.
Publicado: (2023)

Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro
por: Kapteijn, Maaike Y., et al.
Publicado: (2023)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro
por: Fuchs, Daniel, et al.
Publicado: (2023)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
por: Fishman, Hila, et al.
Publicado: (2023)

ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
por: Yamamuro, Shun, et al.
Publicado: (2019)

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance
por: Yamamuro, Shun, et al.
Publicado: (2021)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Cerebral metastases of cutaneous melanoma.
por: Gupta, G., et al.
Publicado: (1997)

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
por: Punt, C. J., et al.
Publicado: (1997)

A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response
por: Vestermark, LW, et al.
Publicado: (2008)

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
por: Tremont-Lukats, Ivo W., et al.
Publicado: (2019)

Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma
por: Lin, Kun-I, et al.
Publicado: (2018)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
por: Eisen, T, et al.
Publicado: (2006)

Lung toxicity of lomustine in the treatment of progressive gliomas
por: Seliger, Corinna, et al.
Publicado: (2022)

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
por: Azzabi, A, et al.
Publicado: (2005)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Temozolomide for the treatment of metastatic melanoma
por: Quirbt, I., et al.
Publicado: (2007)

Cerebral metastases of malignant mesothelioma
por: Bathini, Abhijith, et al.
Publicado: (2022)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

MALIGNANT MELANOMA – CUTANEOUS METASTASES
por: Padmavathy, L, et al.
Publicado: (2008)

Metastases of malignant melanoma to stomach
por: Kuzu, Ufuk Barıs, et al.
Publicado: (2016)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
por: Morris, S L, et al.
Publicado: (2004)

Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
por: Kraehn, G M, et al.
Publicado: (2001)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
por: Beije, N, et al.
Publicado: (2015)

Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
por: Burton, J.H., et al.
Publicado: (2015)

Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells
por: Chakkath, Thushara, et al.
Publicado: (2015)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2017)

Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma
por: Smallwood, Katherine, et al.
Publicado: (2020)

Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases
por: Seifert, Heike, et al.
Publicado: (2015)

Stereotactic radiosurgery for brain metastases from malignant melanoma
por: Christ, Sebastian M., et al.
Publicado: (2015)

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
por: Siena, S., et al.
Publicado: (2010)

Tracking and Treating Malignant Melanoma Metastases
por: Piérard, Gérald E., et al.
Publicado: (2012)

Malignant Melanoma Metastasizes to Colonic Polyp
por: Azharuddin, Muhammad, et al.
Publicado: (2018)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jb9r7u0e78n5j2o2dueg55s9cp